Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron, Solifenacin, Tadalafil and Combination in Female OAB
NCT06184334Completed
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron, Tadalafil and Solifenacin (3 arms). Primary endpoint: Overactive Bladder Symptoms Score at 3 months. Started Sep 2022; status: completed.
02
Drugs
mirabegronsolifenacintadalafil
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT06184334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184334.